Knight Therapeutics | GUD - Net Income


Knight Therapeutics reported CAD-3.79M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acasti Pharma USD -938K 2.42M Sep/2025
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alaunos Therapeutics USD -1.16M 108K Sep/2025
Aurora Cannabis CAD 1.82M 53.29M Dec/2025
Avita Medical AUD -11.62M 1.7M Dec/2025
Canopy Growth CAD -62.63M 60.99M Dec/2025
Cronos Group USD 13.75M 15.57M Mar/2026
Dianthus Therapeutics USD -64.43M 27.67M Dec/2025
Ionis Pharmaceuticals USD -93M 136M Mar/2026
IQVIA Holdings USD 274M 240M Mar/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Moderna USD -1.34B 517M Mar/2026
Omeros USD -32.23M 23.81M Sep/2024
Organigram Holdings CAD 19.97M 57.93M Dec/2025
Organon & Co USD -205M 365M Dec/2025
Revvity USD 40.72M 57.65M Mar/2026
Tectonic Therapeutic USD -19.23M 186K Dec/2025
Tilray USD -44.93M 44.61M Sep/2025
Viatris USD 176.4M 516.5M Mar/2026
Xeris Pharmaceuticals USD 11.08M 10.46M Dec/2025